Zachary Conrad Hartman | Scholars@Duke

Zachary Conrad Hartman
Assistant Professor of Surgery

My research interests encompass studies of immunity and inflammation in the context of developing and established cancers. These research interests involve studies of inflammation in the genesis and maintenance of specific cancer types (principally breast and ovarian), as well as the impact of inflammation on tumor metastasis and the tumor microenvironment. My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies and development of vaccines to specific oncogenic targets. The major focus of my lab is in uncovering strategies to modulate tumor-derived inflammation and tumor-specific immunity that will translate into clinically efficacious therapies in patients.

Current Appointments & Affiliations

Assistant Professor of Surgery, Surgery, Surgical Sciences, Surgery 2012
Assistant Professor in Pathology, Pathology, Clinical Science Departments 2018

Contact Information

Box 2606 Med Ctr, Durham, NC 27710
Research Drive, Msrbi Rm 414, Durham, NC 27710
zachary.hartman@duke.edu (919) 613-9110

Background
Education, Training, & Certifications
- Post Doctoral Fellow, Md Anderson Cancer Center, University of Texas Medical School at Houston 2010 - 2012
- Post-Doctoral Fellow, Duke University 2006 - 2010
- Ph.D., Duke University 2006
Duke Appointment History
- Instructor, Temporary in the Department of Surgery, Surgery, Surgical Sciences, Surgery 2012
Research
Selected Grants
- Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2021
- A Neoepitope Subunit Vaccine Targeting the Mutated Estrogen Receptor Ligand Binding Domain to Treat and Prevent Endocrine Resistant ER+ Breast Cancer awarded by Department of Defense 2018 - 2021
- Immunotherapeutic Targeting of a Therapy Resistant Oncogenic HER2 Isoform awarded by Susan G. Komen Breast Cancer Foundation 2017 - 2020
- Study of LAMP Vaccines in HER2+ Breast Cancer awarded by Immunomic Therapeutics, Inc. 2017 - 2018
- Mechanisms of Action and Resistance to PD-1 Immunotherapies in Breast Cancer awarded by Merck 2017 - 2018
- Oncogenic Signaling Networks awarded by Department of Defense 2012 - 2018
- Investigating Adaptive Immune Recognition of Dormant Disseminated Tumor Cells awarded by Fred Hutchinson Cancer Research Center 2017 - 2018
- Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
Publications & Artistic Works
Selected Publications
- Conference Papers
  - Hartman, Z, Crosby, E, Wei, J-P, Yang, X-Y, Lei, G-J, Wang, T, Liu, C-X, Agarwal, P, Morse, M, and Lyerly, H. "Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer." February 15, 2017. Full Text
  - Crosby, EJ, Wei, J, Yang, XY, Lei, G, Wang, T, Liu, C-X, Agarwal, P, Lyerly, HK, and Hartman, ZC. "Abstract A38: Checkpoint blockade elicits unique T cell expansion to promote tumor regression." February 2017. Full Text
  - Kessler, JD, Kahle, KT, Sun, T, Meerbrey, KL, Schlabach, MR, Schmitt, EM, Skinner, SO, Xu, Q, Li, MZ, Hartman, ZC, Rao, M, Yu, P, Dominguez-Vidana, R, Liang, AC, Solimin, NL, Bernardi, RJ, Yu, B, Hsu, T, Golding, I, Luo, J, Osborne, CK, Creighton, C, Hilsenbeck, SG, Schiff, R, Shaw, CA, Elledge, SJ, and Westbrook, TF. "A sumoylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis." April 15, 2012. Full Text Link to Item
  - Seregin, SS, Hartman, ZC, Appledorn, DM, Aldhamen, YA, Schuldt, NJ, Bujold, M, Godbehere, S, and Amalfitano, A. "Improved Safety Profile of Novel Adenovirus Based Vectors "Capsid-displaying" Complement Inhibitors: Increased Potential for Cardiovascular Gene Transfer Applications." November 3, 2009. Link to Item
  - Hartman, ZC, Mendelson, T, and Amalfitano, A. "19. A New, Plasmid-Based Adenoviral Vectoring System Derived from the Highly Immunogenic, Human Ad4 Strain." 2006. Full Text
- Journal Articles
  - Crosby, EJ, Wei, J, Yang, XY, Lei, G, Wang, T, Liu, CX, Agarwal, P, Korman, AJ, Morse, MA, Gouin, K, Knott, SRV, Lyerly, HK, and Hartman, ZC. "Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors (Accepted)." OncoImmunology (January 19, 2018). Full Text
  - Shuptrine, CW, Ajina, R, Fertig, EJ, Jablonski, SA, Kim Lyerly, H, Hartman, ZC, and Weiner, LM. "An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection." Cancer immunology, immunotherapy : CII 66, no. 12 (December 2017): 1529-1544. Full Text
  - Osada, T, Morse, MA, Hobeika, A, Diniz, MA, Gwin, WR, Hartman, Z, Wei, J, Guo, H, Yang, X-Y, Liu, C-X, Kaneko, K, Broadwater, G, and Lyerly, HK. "Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition." Oncoimmunology 6, no. 6 (January 2017): e1315495-. Full Text
  - Ren, J, Gwin, WR, Zhou, X, Wang, X, Huang, H, Jiang, N, Zhou, L, Agarwal, P, Hobeika, A, Crosby, E, Hartman, ZC, Morse, MA, H Eng, K, and Lyerly, HK. "Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy." Oncoimmunology 6, no. 4 (January 2017): e1264563-. Full Text
  - Turpin, J, Ling, C, Crosby, EJ, Hartman, ZC, Simond, AM, Chodosh, LA, Rennhack, JP, Andrechek, ER, Ozcelik, J, Hallett, M, Mills, GB, Cardiff, RD, Gray, JW, Griffith, OL, and Muller, WJ. "The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment." Oncogene 35, no. 47 (November 2016): 6053-6064. Full Text
  - Mazumdar, A, Poage, GM, Shepherd, J, Tsimelzon, A, Hartman, ZC, Den Hollander, P, Hill, J, Zhang, Y, Chang, J, Hilsenbeck, SG, Fuqua, S, Kent Osborne, C, Mills, GB, and Brown, PH. "Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion." Breast cancer research and treatment 158, no. 3 (August 2016): 441-454. Full Text
  - Zhao, J, Zhao, D, Poage, GM, Mazumdar, A, Zhang, Y, Hill, JL, Hartman, ZC, Savage, MI, Mills, GB, and Brown, PH. "Death-associated protein kinase 1 promotes growth of p53-mutant cancers." The Journal of clinical investigation 125, no. 7 (July 2015): 2707-2720. Full Text
  - Osada, T, Nagaoka, K, Takahara, M, Yang, XY, Liu, C-X, Guo, H, Roy Choudhury, K, Hobeika, A, Hartman, Z, Morse, MA, and Lyerly, HK. "Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors." Journal of immunotherapy (Hagerstown, Md. : 1997) 38, no. 4 (May 2015): 155-164. Full Text
  - Barrott, JJ, Hughes, PF, Osada, T, Yang, X-Y, Hartman, ZC, Loiselle, DR, Spector, NL, Neckers, L, Rajaram, N, Hu, F, Ramanujam, N, Vaidyanathan, G, Zalutsky, MR, Lyerly, HK, and Haystead, TA. "Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells." Chem Biol 20, no. 9 (September 19, 2013): 1187-1197. Full Text Link to Item
  - Hartman, ZC, Poage, GM, den Hollander, P, Tsimelzon, A, Hill, J, Panupinthu, N, Zhang, Y, Mazumdar, A, Hilsenbeck, SG, Mills, GB, and Brown, PH. "Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8." Cancer Res 73, no. 11 (June 1, 2013): 3470-3480. Full Text Link to Item
  - Poage, GM, Hartman, ZC, and Brown, PH. "Revealing targeted therapeutic opportunities in triple-negative breast cancers: A new strategy." Cell Cycle 12, no. 17 (2013): 2705-2706. Full Text
  - Kessler, JD, Kahle, KT, Sun, T, Meerbrey, KL, Schlabach, MR, Schmitt, EM, Skinner, SO, Xu, Q, Li, MZ, Hartman, ZC, Rao, M, Yu, P, Dominguez-Vidana, R, Liang, AC, Solimini, NL, Bernardi, RJ, Yu, B, Hsu, T, Golding, I, Luo, J, Osborne, CK, Creighton, CJ, Hilsenbeck, SG, Schiff, R, Shaw, CA, Elledge, SJ, and Westbrook, TF. "A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis." Science 335, no. 6066 (2012): 348-353. Full Text
  - Hartman, ZC, Wei, J, Glass, OK, Guo, H, Lei, G, Yang, X-Y, Osada, T, Hobeika, A, Delcayre, A, Le Pecq, J-B, Morse, MA, Clay, TM, and Lyerly, HK. "Increasing vaccine potency through exosome antigen targeting." Vaccine 29, no. 50 (November 21, 2011): 9361-9367. Full Text Link to Item
  - Xia, W, Liu, Z, Zong, R, Liu, L, Zhao, S, Bacus, SS, Mao, Y, He, J, Wulfkuhle, JD, Petricoin, EF, Osada, T, Yang, X-Y, Hartman, ZC, Clay, TM, Blackwell, KL, Lyerly, HK, and Spector, NL. "Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors." Mol Cancer Ther 10, no. 8 (August 2011): 1367-1374. Full Text Link to Item
  - Hartman, ZC, Yang, X-Y, Glass, O, Lei, G, Osada, T, Dave, SS, Morse, MA, Clay, TM, and Lyerly, HK. "HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis." Cancer Res 71, no. 13 (July 1, 2011): 4380-4391. Full Text Link to Item
  - Clay, TM, Osada, T, Hartman, ZC, Hobeika, A, Devi, G, Morse, MA, and Lyerly, HK. "Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines." Immunol Res 49, no. 1-3 (April 2011): 235-247. Full Text Link to Item
  - Hartman, ZC, Osada, T, Glass, O, Yang, XY, Lei, G-J, Lyerly, HK, and Clay, TM. "Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity." Cancer Res 70, no. 18 (September 15, 2010): 7209-7220. Full Text Link to Item
  - Gabitzsch, ES, Xu, Y, Balint, JP, Hartman, ZC, Lyerly, HK, and Jones, FR. "Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA." Cancer Immunol Immunother 59, no. 7 (July 2010): 1131-1135. Full Text Link to Item
  - Morse, MA, Wei, J, Hartman, Z, Xia, W, Ren, X-R, Lei, G, Barry, WT, Osada, T, Hobeika, AC, Peplinski, S, Jiang, H, Devi, GR, Chen, W, Spector, N, Amalfitano, A, Lyerly, HK, and Clay, TM. "Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo." Int J Cancer 126, no. 12 (June 15, 2010): 2893-2903. Full Text Link to Item
  - Hartman, ZC, Wei, J, Osada, T, Glass, O, Lei, G, Yang, X-Y, Peplinski, S, Kim, D-W, Xia, W, Spector, N, Marks, J, Barry, W, Hobeika, A, Devi, G, Amalfitano, A, Morse, MA, Lyerly, HK, and Clay, TM. "An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity." Clin Cancer Res 16, no. 5 (March 1, 2010): 1466-1477. Full Text Link to Item
  - Seregin, SS, Aldhamen, YA, Appledorn, DM, Hartman, ZC, Schuldt, NJ, Scott, J, Godbehere, S, Jiang, H, Frank, MM, and Amalfitano, A. "Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo." Blood 116, no. 10 (2010): 1669-1677. Full Text
  - Seregin, SS, Hartman, ZC, Appledorn, DM, Godbehere, S, Jiang, H, Frank, MM, and Amalfitano, A. "Novel adenovirus vectors 'Capsid-Displaying' a human complement inhibitor." Journal of Innate Immunity 2, no. 4 (2010): 353-359. Full Text
  - Osada, T, Yang, XY, Hartman, ZC, Glass, O, Hodges, BL, Niedzwiecki, D, Morse, MA, Lyerly, HK, Amalfitano, A, and Clay, TM. "Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity." Cancer Gene Ther 16, no. 9 (September 2009): 673-682. Full Text Link to Item
  - Osada, T, Woo, CY, McKinney, M, Yang, XY, Lei, G, Labreche, HG, Hartman, ZC, Niedzwiecki, D, Chao, N, Amalfitano, A, Morse, MA, Lyerly, HK, and Clay, TM. "Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine." Clin Cancer Res 15, no. 8 (April 15, 2009): 2789-2796. Full Text Link to Item
  - Cohen, TJ, Barrientos, T, Hartman, ZC, Garvey, SM, Cox, GA, and Yao, T-P. "The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity." FASEB J 23, no. 1 (January 2009): 99-106. Full Text Link to Item
  - Hartman, ZC, Appledorn, DM, Serra, D, Glass, O, Mendelson, TB, Clay, TM, and Amalfitano, A. "Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system." Virology 374, no. 2 (May 10, 2008): 453-467. Full Text Link to Item
  - Hartman, ZC, Appledorn, DM, and Amalfitano, A. "Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications." Virus Res 132, no. 1-2 (March 2008): 1-14. (Review) Full Text Link to Item
  - Hartman, ZC, Black, EP, and Amalfitano, A. "Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells." Virology 358, no. 2 (February 20, 2007): 357-372. Full Text Link to Item
  - Hartman, ZC, Kiang, A, Everett, RS, Serra, D, Yang, XY, Clay, TM, and Amalfitano, A. "Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo." J Virol 81, no. 4 (February 2007): 1796-1812. Full Text Link to Item
  - Kiang, A, Hartman, ZC, Everett, RS, Serra, D, Jiang, H, Frank, MM, and Amalfitano, A. "Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system." Mol Ther 14, no. 4 (October 2006): 588-598. Full Text Link to Item
  - Kiang, A, Hartman, ZC, Liao, S, Xu, F, Serra, D, Palmer, DJ, Ng, P, and Amalfitano, A. "Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice." Mol Ther 13, no. 1 (January 2006): 127-134. Full Text Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

Selected Publications

Conference Papers

Journal Articles